These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15456955)

  • 1. Intensive chemotherapy in the treatment of aggressive diffuse large B-cell lymphoma: malignant lymphoma.
    Avilés A; Nambo MJ; Neri N; Talavera A; Castañeda C; Murillo E; Cleto S; Huerta-Guzmán J
    Med Oncol; 2004; 21(3):269-72. PubMed ID: 15456955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined therapy in the treatment of primary mediastinal B-cell lymphoma: conventional versus escalated chemotherapy.
    Avilés A; García EL; Fernández R; Gonzalez JL; Neri N; Díaz-Maqueo JC
    Ann Hematol; 2002 Jul; 81(7):368-73. PubMed ID: 12185505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epirubicin (CEOP-Bleo) versus idaurubicin (CIOP-Bleo) in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma: dose escalation studies.
    Avilés A; Nambo MJ; Talavera A; Garcia EL; Huerta-Guzman J; Díaz Maqueo JC
    Anticancer Drugs; 1997 Nov; 8(10):937-42. PubMed ID: 9436636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma.
    Avilés A; Neri N; Castañeda C; Talavera A; Huerta-Guzmán J; González M
    Med Oncol; 2002; 19(1):55-8. PubMed ID: 12025891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP-BLEO regimens.
    Avilés A; Cleto S; Huerta-Guzmán J; Neri N
    Eur J Haematol; 2001 Feb; 66(2):94-9. PubMed ID: 11168516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose escalation of epirubicin in the CEOP-BLEO regimen: a controlled clinical trial comparing standard doses for the treatment of diffuse large cell lymphoma.
    Avilés A; Calva A; Díaz-Maqueo JC; Talavera A; Huerta-Guzmán J; Vásquez E
    Leuk Lymphoma; 1997 Apr; 25(3-4):319-25. PubMed ID: 9168442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
    Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
    Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy for the treatment of patients with primary high grade gastric B-cell lymphoma of modified Ann Arbor Stages IE and IIE.
    Raderer M; Valencak J; Osterreicher C; Drach J; Hejna M; Kornek G; Scheithauer W; Brodowicz T; Chott A; Dragosics B
    Cancer; 2000 May; 88(9):1979-85. PubMed ID: 10813708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A weekly alternating chemotherapy regimen with low toxicity for the treatment of aggressive lymphoma.
    Bower M; Brock C; Gulliford T; O'Reilly SM; Smith DB; Newlands ES
    Cancer Chemother Pharmacol; 1996; 38(1):106-9. PubMed ID: 8603443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of cyclophosphamide,epirubicin, vincristine, prednisone, and etoposide (CEOP-E) for aggressive non-Hodgkin 's lymphoma.
    Kim JG; Sohn SK; Kim DH; Baek JH; Park TI; Lee KB
    J Korean Med Sci; 2004 Dec; 19(6):820-5. PubMed ID: 15608392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acquired immunodeficiency syndrome-related lymphoma with a standard chemotherapy regimen.
    Avilés A; Nambo MJ; Halabe J
    Ann Hematol; 1999 Jan; 78(1):9-12. PubMed ID: 10037262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100): a phase II study.
    Basaran M; Bavbek ES; Sakar B; Eralp Y; Alici S; Tas F; Yaman F; Dogan O O; Camlica H; Onat H
    Am J Clin Oncol; 2001 Dec; 24(6):570-5. PubMed ID: 11801756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Dose Chemotherapy in the Treatment of Poor Prognosis Malignant Lymphoma.
    Avilés A; Talavera A; Díaz-Maqueo JC; Cleto S; Díaz NR; García EL
    Hematology; 1998; 3(3):229-33. PubMed ID: 27416532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma.
    Fierro MT; Doveil GC; Quaglino P; Savoia P; Verrone A; Bernengo MG
    Dermatology; 1997; 194(3):268-72. PubMed ID: 9187846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon alpha 2b as maintenance therapy improves outcome in follicular lymphoma.
    Avilés A; Neri N; Huerta-Guzmán J; Pérez F; Sotelo L
    Leuk Lymphoma; 2004 Nov; 45(11):2247-51. PubMed ID: 15512813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone.
    Rossini F; Terruzzi E; Perego D; Miccolis I; Rivolta F; Manca E; Pogliani EM
    Cancer; 2004 Jan; 100(2):350-5. PubMed ID: 14716771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14 +R) in high-risk diffuse large cell lymphoma.
    Avilés A; Nambo MJ; Neri N; Cleto S; Castañeda C; Huerta-Guzmàn J; Murillo E; Contreras M; Talavera A; González M
    Med Oncol; 2007; 24(1):85-9. PubMed ID: 17673816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast lymphoma.
    Avilés A
    Ann Oncol; 2008 Jul; 19(7):1360. PubMed ID: 18579558
    [No Abstract]   [Full Text] [Related]  

  • 20. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
    Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
    J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.